Status:
UNKNOWN
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
Eligibility Criteria
Inclusion
- Histological diagnosis of thoracic Esophageal squamous cell carcinoma
- ECOG performance status 0-1
- Age 18-75 years
- Resectable disease, cT2-4aNanyM0 or cT1-3N+M0
- Life expectancy more than 6 months
- Use of an effective contraceptive for adults to prevent pregnancy
Exclusion
- Not suitable for surgery
- Prior chemotherapy, radiotherapy and immune-oncology therapies for ESCC
- Prior esophageal, gastric, or gastro-esophageal junction surgery
- Esophageal ulcer, esophageal perforation，chest pain（≥middle level）
- Pregnant or lactating women
Key Trial Info
Start Date :
August 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04506138
Start Date
August 11 2020
End Date
December 31 2025
Last Update
December 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022